Immunomodulating drugs for the treatment of cancer

Research output: Book/ReportBook

Abstract

Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine. The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well. Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients. A companion website offers the fully searchable text and an image bank.

Original languageEnglish (US)
PublisherWolters Kluwer Health Adis (ESP)
Number of pages312
ISBN (Electronic)9781451153613
ISBN (Print)9781605473338
StatePublished - Mar 29 2012
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Neoplasms
Therapeutics
Patient Care
Textbooks
Hematologic Diseases
Antineoplastic Agents
Biological Availability
Primary Health Care
Age Groups
Research Personnel
Medicine
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Immunomodulating drugs for the treatment of cancer. / Chanan Khan, Asher A.

Wolters Kluwer Health Adis (ESP), 2012. 312 p.

Research output: Book/ReportBook

Chanan Khan AA. Immunomodulating drugs for the treatment of cancer. Wolters Kluwer Health Adis (ESP), 2012. 312 p.
Chanan Khan, Asher A. / Immunomodulating drugs for the treatment of cancer. Wolters Kluwer Health Adis (ESP), 2012. 312 p.
@book{c8d2bd2fbf634eb581fe918d3964d115,
title = "Immunomodulating drugs for the treatment of cancer",
abstract = "Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine. The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well. Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients. A companion website offers the fully searchable text and an image bank.",
author = "{Chanan Khan}, {Asher A}",
year = "2012",
month = "3",
day = "29",
language = "English (US)",
isbn = "9781605473338",
publisher = "Wolters Kluwer Health Adis (ESP)",

}

TY - BOOK

T1 - Immunomodulating drugs for the treatment of cancer

AU - Chanan Khan, Asher A

PY - 2012/3/29

Y1 - 2012/3/29

N2 - Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine. The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well. Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients. A companion website offers the fully searchable text and an image bank.

AB - Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine. The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well. Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients. A companion website offers the fully searchable text and an image bank.

UR - http://www.scopus.com/inward/record.url?scp=84974559509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974559509&partnerID=8YFLogxK

M3 - Book

AN - SCOPUS:84974559509

SN - 9781605473338

BT - Immunomodulating drugs for the treatment of cancer

PB - Wolters Kluwer Health Adis (ESP)

ER -